2C-T-7

Pre-existing cardiovascular disease, hypertension, or cardiac arrhythmias represent relative contraindications. One fatality involved cerebral hemorrhage.

Epilepsy and other seizure disorders represent a relative contraindication. Seizures were documented in at least one 2C-T-7-associated fatality (with MDMA co-ingestion). MAO inhibitory activity may further contribute to seizure risk.

Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder) is an absolute contraindication. 5-HT₂A agonists can precipitate acute psychosis or destabilise latent psychotic illness.

Bipolar disorder is an absolute contraindication due to risk of manic episode precipitation and the dangerous interaction between 2C-T-7 and lithium.

Hepatic impairment is a relative contraindication. CYP2D6-mediated metabolism occurs in the liver, and impairment may alter the compound's pharmacokinetic profile.

Pregnancy and breastfeeding are absolute contraindications. No reproductive or developmental safety data exist for 2C-T-7.

Adolescence is a relative contraindication. No safety data exist for minors. One documented fatality involved a 17-year-old.

Concurrent use of any MAO inhibitor (phenelzine, tranylcypromine, selegiline, moclobemide, harmine/harmaline) is absolutely contraindicated.

Concurrent MDMA use is absolutely contraindicated. Two of three documented fatalities involved MDMA co-ingestion.

Concurrent use of SSRIs, SNRIs, tramadol, linezolid, or dextromethorphan represents a relative contraindication due to serotonin syndrome risk.